Why is ADHD a Greater Risk for Substance Misuse?

ADHD & Substance Misuse: the Connection

Why is ADHD a Greater Risk for Substance Misuse?

ADHD is one of the psychiatric conditions most consistently associated with later substance misuse and substance use disorder (SUD). The relationship is not adequately explained by a single idea such as “impulsivity”, “low dopamine” or “self-medication”. Current thinking is that ADHD increases addiction vulnerability through an interaction between neurodevelopmental reward-processing differences, impaired inhibitory control, delay aversion, emotional dysregulation, greater exposure to adverse social and behavioural pathways, psychiatric comorbidity, sleep disturbance and the reinforcing effects of substances themselves.

The association is clinically substantial. A large meta-analytic review of adult psychiatric comorbidity found that adults with ADHD had around 4.6 times the odds of having a substance use disorder compared with adults without ADHD. (PubMed) Conversely, ADHD is markedly overrepresented in addiction services: contemporary meta-analysis estimates that approximately one in five people receiving treatment for SUD also meet criteria for ADHD. (PubMed)

Importantly, this is an association at population level. Most people with ADHD do not develop an addiction, and ADHD should never be interpreted as implying addictive behaviour.

1. ADHD Alters the Balance Between Immediate and Delayed Reward

One of the most useful ways of understanding the ADHD–addiction relationship is through reward processing.

The brain continuously evaluates whether a behaviour is worth repeating. Dopamine is important within this system, particularly across mesocorticolimbic and frontostriatal networks involving the ventral tegmental area, nucleus accumbens, striatum and prefrontal cortex.

ADHD is associated with differences in the regulation of reward, motivation and reinforcement. Many people with ADHD show a stronger behavioural preference for:

smaller rewards now

rather than:

larger rewards later.

This is often referred to as delay discounting or, in some ADHD models, delay aversion.

That matters in addiction because psychoactive substances can provide an unusually rapid and reliable reward.

Alcohol can produce relaxation within minutes. Nicotine can produce rapid changes in arousal and attention. Cocaine and amphetamine rapidly increase catecholaminergic activity. Cannabis can change subjective arousal, thought and emotional state. Opioids can rapidly suppress physical and emotional distress.

By comparison, many healthy rewards require prolonged effort:

study → qualification → career benefit
exercise → gradual health improvement
saving → future financial security
relationship work → longer-term intimacy.

For someone whose motivational system is particularly sensitive to immediacy, novelty and salience, drugs can therefore compete very effectively against delayed natural rewards.

This does not mean that people with ADHD are simply “pleasure seeking”. In many cases substances become powerful because they provide rapid state-change, not merely euphoria.

2. ADHD is Not Simply a “Low Dopamine Disorder”

It is tempting to explain addiction in ADHD as:

ADHD = low dopamine → drugs increase dopamine → addiction.

That is too simplistic.

ADHD involves altered functioning across dopaminergic and noradrenergic neural networks, particularly those involved in executive control, attention, reward anticipation, motivation and behavioural reinforcement. The abnormalities are dynamic and circuit-specific rather than representing a uniform deficiency of dopamine throughout the brain.

Addictive drugs interact with many of these same circuits.

For example:

Nicotine activates nicotinic acetylcholine receptors and indirectly increases dopamine release.

Cocaine blocks dopamine transporters and produces a rapid increase in synaptic dopamine.

Amphetamine and methamphetamine increase monoamine release and reverse transporter function.

Alcohol affects GABA, glutamate, endogenous opioid and dopamine systems.

Cannabis acts primarily through cannabinoid CB1 receptors but indirectly alters dopamine and multiple other neurotransmitter systems.

Opioids act principally through opioid receptors but strongly engage reward circuitry downstream.

Thus, ADHD and addiction overlap at the level of reward, reinforcement and executive-control networks, rather than because every person with ADHD simply has inadequate dopamine.

3. Impulsivity Increases the Probability of Trying Substances

ADHD is associated with several forms of impulsivity, including:

motor impulsivity – acting before stopping to think;

decision-making impulsivity – choosing immediate rewards despite greater future costs;

emotional impulsivity – acting rapidly during anger, excitement or distress;

attentional impulsivity – rapidly switching toward novel or salient stimuli.

These characteristics increase the likelihood of:

trying a substance when offered;

using more than originally intended;

making decisions while intoxicated;

combining substances;

returning to use despite previous consequences;

and responding rapidly to craving.

The first exposure to a drug is obviously not addiction. However, repeated impulsive choices increase the number of opportunities for reinforcement learning to occur.

4. Poor Inhibitory Control Makes “Stopping” Harder

ADHD is associated with difficulties in executive functions including:

response inhibition;

working memory;

planning;

prospective memory;

attention regulation;

and self-monitoring.

Addiction progressively places increasing demands on exactly these functions.

A person may fully intend:

“I will only have two drinks.”

But maintaining that decision requires the individual to hold the goal in working memory, monitor intake, inhibit subsequent urges and tolerate the delay before the next reward.

Alcohol then further reduces inhibitory control.

This creates a particularly problematic interaction:

ADHD-related executive vulnerability → substance use → acute impairment of executive control → further substance use.

Repeated cycles can gradually shift behaviour from voluntary recreational use towards compulsive patterns.

5. ADHD Brains Can Be Particularly Sensitive to Boredom and Under-Stimulation

Boredom is clinically important and often underestimated.

Many adults with ADHD describe ordinary environments as insufficiently stimulating unless there is:

novelty;

urgency;

challenge;

risk;

high emotional intensity;

competition;

or immediate reward.

Substances provide powerful changes in internal stimulation.

A stimulant may increase alertness and drive.

Nicotine may produce brief increases in concentration and arousal.

Alcohol may make an otherwise unstimulating social situation feel more rewarding.

Cannabis may alter perception and thought.

Cocaine may generate intense stimulation and confidence.

This helps explain why substance use can become linked not only to distress but also to under-stimulation.

In other words, some substance use is not:

“I feel terrible and need to escape.”

It can instead be:

“Nothing is happening and I need something to happen.”

That distinction is particularly relevant in ADHD.

6. Emotional Dysregulation Creates Another Route Into Substance Use

Although emotional dysregulation is not a core DSM-5-TR diagnostic criterion for ADHD, it is frequently clinically important.

People with ADHD may experience:

rapid escalation of emotion;

low frustration tolerance;

irritability;

difficulty disengaging from upsetting thoughts;

intense reactions to interpersonal conflict;

and slower return to emotional baseline.

Substances can become extremely efficient short-term regulators of these states.

For example:

alcohol may suppress anxiety and self-consciousness;

cannabis may temporarily reduce internal tension;

benzodiazepines may rapidly reduce anxiety and physiological arousal;

stimulants may temporarily reduce subjective chaos or increase confidence and organisation;

opioids may produce powerful emotional detachment and relief.

The danger is that the brain learns:

distress → substance → rapid relief.

That is negative reinforcement.

The substance is not necessarily being taken because the person wants to become intoxicated. It may increasingly be taken because the absence of the substance has become associated with discomfort.

7. “Self-Medication” is Real — But It Should Not Explain Everything

The self-medication hypothesis has an important place in ADHD and addiction but is often overstated.

Some people clearly discover that particular substances temporarily alter symptoms they find difficult.

Examples include using:

nicotine to increase concentration;

cannabis to reduce mental restlessness or facilitate sleep;

alcohol to reduce social tension or internal hyperactivity;

illicit stimulants to improve alertness, organisation or productivity.

The UK ADHD Partnership expert consensus acknowledges that substances may sometimes be used for perceived functional or psychological effects, and emphasises the importance of asking what the substance is doing for the individual, rather than simply recording quantity and frequency. (PubMed)

However, not every addiction in ADHD represents conscious self-treatment.

Substance use may instead arise from:

peer exposure;

sensation seeking;

social environment;

impulsivity;

trauma;

conduct disorder;

genetic liability;

or repeated recreational reinforcement.

Most patients probably have several interacting pathways.

8. ADHD Can Accelerate the Transition From Experimentation to Disorder

The clinically important issue is not merely that individuals with ADHD may experiment with drugs more often.

ADHD has historically been associated with a more problematic trajectory of substance use, including earlier initiation and more severe or complicated addiction in some populations.

The pattern can be conceptualised as:

earlier experimentation

→ greater frequency of use

→ more rapid reinforcement

→ impaired control

→ earlier functional consequences

→ SUD.

Among people with established drug dependence, ADHD has been associated with earlier first substance use, more substance-dependence diagnoses and greater psychiatric morbidity. (PubMed)

Contemporary addiction research therefore increasingly regards ADHD as a clinically meaningful course modifier, not merely another diagnosis sitting alongside SUD.

9. Conduct Disorder is an Important—but Incomplete—Part of the Explanation

One of the strongest developmental pathways to addiction involves childhood conduct disorder and antisocial behaviour.

Children with ADHD have higher rates of oppositional and conduct problems than children without ADHD. Conduct disorder itself predicts:

earlier substance exposure;

risk-taking;

antisocial peer affiliation;

school exclusion;

criminal involvement;

and later SUD.

Historically this raised an important question:

Is ADHD itself responsible for the increased addiction risk, or is the association entirely explained by conduct disorder?

The best evidence suggests that conduct disorder explains part, but not all, of the relationship.

ADHD appears to retain an independent association with adverse substance outcomes even after conduct symptoms are considered, although risk becomes particularly high when ADHD and conduct disorder coexist.

A 2025 systematic review of childhood predictors of adult psychiatric outcomes in people with ADHD continues to support the importance of developmental comorbidity when assessing later SUD risk. (PubMed)

10. Psychiatric Comorbidity Amplifies Risk Further

ADHD rarely occurs in isolation.

Common coexisting conditions include:

depression;

anxiety;

PTSD;

bipolar disorder;

personality disorder;

autism;

sleep disorders;

and conduct or antisocial disorders.

Each can alter substance-use risk.

Recent population-level evidence demonstrates that SUD is substantially more common in ADHD when additional psychiatric disorders are present. A large 2025 study found ADHD was associated with increased SUD prevalence across substance categories in both sexes, with particularly large increases where ADHD co-occurred with conditions such as personality disorders or psychotic disorders. (PubMed)

Clinically, therefore, an individual with:

ADHD + emotional dysregulation + trauma + depression + social instability

has a very different risk profile from an otherwise well-functioning person with uncomplicated ADHD.

11. Sleep Can Be an Important Hidden Driver

Sleep disturbance is extremely common in ADHD.

Examples include:

delayed sleep timing;

difficulty switching off;

insomnia;

irregular sleep schedules;

restless sleep;

and insufficient sleep.

Sleep deprivation itself worsens:

attention;

working memory;

impulsivity;

emotional regulation;

and reward-based decision making.

People may then use substances bidirectionally:

stimulants, caffeine or nicotine to remain awake during the day;

and

alcohol, cannabis or sedatives to switch off at night.

This can create a pharmacological see-saw:

stimulation during the day → sedation at night → poor-quality sleep → more daytime stimulation.

That cycle can become surprisingly entrenched.

12. Social and Functional Consequences of Untreated ADHD Increase Exposure to Addiction Risk

ADHD can indirectly increase substance risk through its consequences.

Persistent untreated ADHD may contribute to:

academic failure;

school exclusion;

employment instability;

relationship breakdown;

financial problems;

driving offences;

criminal justice involvement;

low self-esteem;

and social marginalisation.

These consequences can increase exposure to environments in which substance use is more prevalent.

They can also generate chronic stress.

Thus ADHD can increase SUD risk through both direct neurobehavioural pathways and secondary psychosocial pathways.

13. Genetics Also Overlap

Both ADHD and SUD are substantially heritable.

There is evidence of shared genetic liability across ADHD, risk-taking behaviour, smoking and several substance-use phenotypes.

This does not mean that an “addiction gene” causes both disorders.

Rather, large numbers of genetic variants influence traits such as:

dopaminergic signalling;

impulsivity;

executive function;

reward sensitivity;

stress response;

and risk taking.

Some of this polygenic liability appears to overlap between ADHD and addiction.

Therefore part of the association is probably pleiotropic: some genetic factors increase vulnerability to both conditions.

14. Nicotine is Particularly Relevant to ADHD

Nicotine deserves special attention because historically it has been one of the substances most strongly associated with ADHD.

Nicotine can transiently alter:

attention;

arousal;

working memory;

and reward processing.

Its pharmacokinetics are also highly reinforcing. When inhaled, nicotine reaches the brain extremely rapidly.

That combination can be particularly attractive to individuals seeking repeated brief changes in concentration or arousal.

Modern nicotine delivery systems also matter. High-strength nicotine vapes can deliver repeated dosing throughout the day without the natural breaks previously imposed by smoking a cigarette.

Thus nicotine dependence can become almost continuous reinforcement.

15. Cannabis and ADHD

Cannabis is one of the clearest contemporary examples of elevated SUD risk.

A 2024 meta-analysis found estimated:

lifetime cannabis use disorder in ADHD: 26.9%

and

current cannabis use disorder: 19.2%.

Compared with controls, individuals with ADHD were approximately 2.85 times more likely to have lifetime CUD and 2.91 times more likely to have current CUD. (PubMed)

This deserves particular clinical attention because patients may report cannabis as improving:

sleep;

anxiety;

restlessness;

or the ability to “switch their brain off.”

Subjective short-term relief does not necessarily imply improvement in ADHD.

Frequent cannabis exposure can itself adversely affect:

attention;

working memory;

motivation;

learning;

and executive functioning.

Those effects may subsequently become difficult to distinguish from ADHD symptoms.

16. Alcohol and ADHD

Alcohol is common partly because it provides rapid:

anxiolysis;

disinhibition;

social facilitation;

and reduction in internal tension.

For an individual with ADHD who experiences social anxiety, internal restlessness or chronic cognitive overload, the reinforcing effects can therefore be powerful.

The problem is that alcohol simultaneously worsens:

impulse control;

judgement;

working memory;

risk assessment;

and emotional regulation.

So the drug used to reduce subjective distress can worsen precisely the executive functions already vulnerable in ADHD.

17. Cocaine and Amphetamine-Type Stimulants

Illicit stimulants require particular clinical nuance.

A person with untreated ADHD may report that cocaine or amphetamine:

“makes me feel normal”;

“slows my brain down”;

“lets me concentrate”;

or

“makes me productive.”

These descriptions are clinically plausible but not diagnostic of ADHD.

People without ADHD may also experience enhanced confidence, vigilance or concentration after stimulant use.

The major difference between therapeutic ADHD stimulant treatment and recreational stimulant use involves:

dose, formulation, route, pharmacokinetic speed, predictability and clinical monitoring.

Rapid delivery produces much greater reinforcement.

Snorted, smoked or injected stimulants produce a rapid rise in brain drug concentration and therefore a much greater euphoric and addictive signal than appropriately prescribed long-acting medication.

18. Benzodiazepines Are an Emerging Area of Concern

Benzodiazepines are particularly relevant where ADHD coexists with:

anxiety;

insomnia;

emotional dysregulation;

or polysubstance use.

A 2025 systematic review and meta-analysis found adults with ADHD had approximately 1.94 times the odds of benzodiazepine misuse or dependence compared with those without ADHD. (PubMed)

This is important because benzodiazepine dependence can develop through repeated use for immediate emotional relief.

The risk becomes considerably greater when benzodiazepines are combined with alcohol, opioids or other sedatives.

19. ADHD is Also Associated With Behavioural Addictions

The same vulnerability may extend beyond drugs.

Problematic:

gambling;

gaming;

internet use;

shopping;

sexual behaviour;

and compulsive eating

have all been investigated in ADHD.

A 2024 clinical study of adults newly diagnosed with ADHD found high rates of at least one behavioural-addiction phenotype, although the precise estimates should not be generalised to the wider ADHD population because this was a selected clinical sample. (PubMed)

The relevance is mechanistic: behaviours capable of delivering rapid, repeated, salient rewards may exploit many of the same vulnerabilities.

A smartphone, gambling app or game can provide reward every few seconds.

That is almost the opposite of the delayed reinforcement structure with which people with ADHD often struggle.

20. Why ADHD and Addiction Can Reinforce Each Other

Once SUD develops, the relationship becomes bidirectional.

Untreated ADHD can impair:

treatment attendance;

appointment keeping;

medication adherence;

planning;

relapse-prevention strategies;

and the ability to implement lifestyle change.

Substance use then worsens:

attention;

memory;

mood;

sleep;

impulse control;

and executive functioning.

The cycle can become:

ADHD symptoms

→ substance use for stimulation/relief

→ temporary reward

→ repeated use

→ worsening sleep/executive function/mood

→ greater ADHD-like impairment

→ increased reliance on substances.

This is why simply treating the addiction while ignoring ADHD can sometimes leave a major relapse driver untreated.

21. Does ADHD Medication Cause Addiction?

This is one of the most important misconceptions to address.

The answer from current evidence is:

appropriately prescribed ADHD medication does not appear to increase the overall risk of subsequently developing a substance use disorder.

A major 2024 US Veterans Affairs systematic evidence review found no evidence that stimulant-treated ADHD patients had a higher subsequent SUD risk than comparable untreated ADHD patients, although the certainty of evidence was limited and data on misuse/diversion remain much thinner. (NCBI)

A 2026 rapid review similarly concluded that longitudinal evidence does not support prescribed stimulant treatment in adolescence causing later SUD. (PubMed)

This distinction is fundamental:

Having ADHD increases addiction risk.

Treating ADHD with prescribed stimulants is not equivalent to creating addiction.

22. Could ADHD Treatment Actually Reduce Substance-Related Harm?

Increasingly, large observational studies suggest that treatment may be associated with lower rather than higher substance-related risk, although observational data cannot prove causation as strongly as randomised trials.

A large Swedish target-trial emulation published in 2025 examined 148,581 people with newly diagnosed ADHD. ADHD medication initiation was associated with a 15% lower rate of substance-misuse events over follow-up: adjusted incidence rate ratio 0.85, 95% CI 0.83–0.87. (PubMed)

The same broad Swedish research programme has also reported lower rates of unnatural-cause mortality among people initiating ADHD medication. (PubMed)

Most recently, a 2026 Swedish within-individual study of 132,666 adults receiving ADHD pharmacotherapy found no signal that starting psychostimulants or atomoxetine increased stimulant-related hospitalisation. In people with a previous stimulant-use disorder, hospitalisation rates were actually lower in the six months after ADHD treatment initiation than before it, although such observational findings should be interpreted cautiously. (PubMed)

So the increasingly defensible clinical position is not:

“Stimulants are protective against addiction.”

It is more nuanced:

There is no good evidence that appropriate stimulant treatment causes SUD, and several large observational datasets suggest ADHD treatment may reduce some substance-related harms.

23. But Prescription Stimulants Still Require Risk Management

None of this means stimulant medication is risk-free.

Possible problems include:

diversion;

taking more than prescribed;

using medication by a non-prescribed route;

combining it with recreational stimulants;

selling medication;

or taking medication specifically for euphoria rather than ADHD treatment.

A 2026 rapid review of adult prescription-stimulant misuse found that misuse continues to occur, particularly among younger adults and people with polysubstance use, although national US estimates suggest past-year misuse has been declining. (PubMed)

The response should therefore be risk management rather than automatic exclusion from treatment.

Long-acting formulations generally have advantages where misuse or diversion is a concern because slower pharmacokinetics reduce the rapid reinforcement associated with immediate-release or non-oral administration.

The UK ADHD Partnership consensus similarly recommends individual risk assessment and generally favours long-acting stimulants when ADHD and SUD coexist. (PubMed)

24. Active Substance Use Does Not Automatically Invalidate an ADHD Diagnosis

This is another important clinical point.

ADHD must have been present developmentally, whereas substance-induced symptoms arise after substance exposure.

But intoxication, withdrawal and chronic substance use can reproduce many ADHD-like symptoms:

poor concentration;

restlessness;

impulsivity;

sleep disturbance;

memory problems;

motivation problems;

and emotional instability.

Assessment therefore needs careful reconstruction of:

childhood symptoms;

school functioning;

pre-substance-use history;

periods of abstinence;

collateral information;

and longitudinal impairment.

Where possible, diagnosis should not rely solely on symptoms reported during acute intoxication or withdrawal.

Nevertheless, requiring prolonged abstinence before ADHD is even considered can create a paradox: untreated ADHD may itself be contributing to continued substance use.

International and UK expert consensus has therefore moved towards integrated assessment and treatment rather than rigid sequential care. (PubMed)

25. ADHD in Addiction Services is Still Commonly Missed

This remains one of the major service-level problems.

ADHD affects only a few percent of the general adult population, yet meta-analysis estimates ADHD in approximately 21–23% of treatment-seeking SUD populations. (PubMed)

In other words:

roughly 1 in 5 addiction-service patients may have ADHD.

This has major implications.

A patient repeatedly described as:

“chaotic”;

“poorly motivated”;

“does not engage”;

“misses appointments”;

or

“doesn't complete treatment plans”

may in some cases have untreated executive dysfunction.

That does not remove personal responsibility, but it changes the clinical formulation and may change treatment.

26. ADHD + SUD Usually Means a More Complex Clinical Course

When ADHD and SUD coexist, clinicians should anticipate greater complexity.

Potential problems include:

earlier substance initiation;

polysubstance use;

poorer treatment retention;

psychiatric comorbidity;

self-harm risk;

criminal justice involvement;

unstable employment and housing;

sleep disturbance;

and difficulties adhering to structured treatment.

A 2026 Swedish study of more than 9,000 individuals with combined ADHD and SUD found they were nearly twice as likely to discontinue ADHD pharmacotherapy within one year as ADHD patients without SUD, and were less likely subsequently to restart treatment. (PubMed)

That finding is important because the group that may particularly need sustained ADHD treatment is also the group at greatest risk of disengaging from it.

The Contemporary Model

The most useful current formulation is therefore:

ADHD does not cause addiction through one pathway.

Instead:

genetic vulnerability

• altered reward processing

• delay discounting

• impulsivity

• executive dysfunction

• novelty and stimulation seeking

• emotional dysregulation

• sleep disturbance

• psychiatric comorbidity

• adverse developmental and social exposures

• rapid pharmacological reinforcement

= increased probability of substance misuse and addiction.

Once substance use becomes established:

intoxication + withdrawal + sleep disruption + cognitive effects + social consequences

can then worsen ADHD functioning and create a self-reinforcing cycle.

The Clinical Message

The most important shift in modern ADHD/addiction thinking is away from:

“This person uses drugs, therefore stimulant treatment is dangerous.”

towards:

“This person has two interacting disorders. What is driving the substance use, how severe and unstable is it, what is the diversion risk, and how can we safely treat both?”

Severe or medically dangerous substance dependence clearly requires urgent addiction management. But ADHD should not routinely be left untreated merely because somebody has a past—or even, in carefully selected circumstances, a current—substance-use disorder.

Assessment should examine:

the substance used;

route;

dose;

frequency;

dependency;

intoxication and withdrawal;

overdose risk;

polysubstance use;

the purpose the substance serves;

previous treatment;

diversion risk;

and whether untreated ADHD is contributing to continued substance use.

Treatment can then combine:

ADHD pharmacotherapy

• SUD-specific treatment

• psychological intervention

• relapse prevention

• sleep treatment

• harm reduction

• practical executive-function support.

That integrated approach is much closer to contemporary evidence than either ignoring the addiction or refusing to treat the ADHD.

Key Figures at a Glance

Key references

Young S, Abbasian C, Al-Attar Z, et al. Identification and treatment of individuals with ADHD and substance use disorder: an expert consensus statement. World Journal of Psychiatry. 2023. (PubMed)

Rieke K, Sereda Y, Mai HJ, et al. ADHD and Substance Use Disorders in Adults. US Department of Veterans Affairs Evidence Synthesis Program, 2024. (NCBI)

Froude AM, Fawcett EJ, et al. The prevalence of cannabis use disorder in attention-deficit hyperactivity disorder: a clinical epidemiological meta-analysis. Journal of Psychiatric Research. 2024. (PubMed)

Zamboni L, Federico A, Casari R, et al. ADHD and the Risk of Benzodiazepine Misuse: A Systematic Review and Meta-Analysis. Substance Use & Misuse. 2025. (PubMed)

Li L, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. 2025. (PubMed)

The evidence base is now strong enough to say that ADHD itself is an important addiction vulnerability, while appropriately prescribed ADHD treatment should not be confused with recreational stimulant exposure or assumed to cause addiction. That distinction is probably the single most important message for a contemporary public-facing ADHD/addiction section.